These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

247 related items for PubMed ID: 25079699

  • 21. Atypical hemolytic uremic syndrome and genetic aberrations in the complement factor H-related 5 gene.
    Westra D, Vernon KA, Volokhina EB, Pickering MC, van de Kar NC, van den Heuvel LP.
    J Hum Genet; 2012 Jul; 57(7):459-64. PubMed ID: 22622361
    [Abstract] [Full Text] [Related]

  • 22. Atypical Hemolytic Uremic Syndrome-Associated FHR1 Isoform FHR1*B Enhances Complement Activation and Inflammation.
    Xu B, Kang Y, Du Y, Guo W, Zhu L, Zhang H.
    Front Immunol; 2022 Jul; 13():755694. PubMed ID: 35126388
    [Abstract] [Full Text] [Related]

  • 23. Complement Genetic Variants and FH Desialylation in S. pneumoniae-Haemolytic Uraemic Syndrome.
    Gómez Delgado I, Corvillo F, Nozal P, Arjona E, Madrid Á, Melgosa M, Bravo J, Szilágyi Á, Csuka D, Veszeli N, Prohászka Z, Sánchez-Corral P.
    Front Immunol; 2021 Jul; 12():641656. PubMed ID: 33777036
    [Abstract] [Full Text] [Related]

  • 24. Molecular basis and outcomes of atypical haemolytic uraemic syndrome in Czech children.
    Štolbová Š, Bezdíčka M, Seeman T, Prohászka Z, Csuka D, Hrachovinová I, Burkert J, Šimánková N, Průhová Š, Zieg J.
    Eur J Pediatr; 2020 Nov; 179(11):1739-1750. PubMed ID: 32424742
    [Abstract] [Full Text] [Related]

  • 25. Development and application of an enzyme-linked immunosorbent assay for the quantitation of alternative complement pathway activation in human serum.
    Mayes JT, Schreiber RD, Cooper NR.
    J Clin Invest; 1984 Jan; 73(1):160-70. PubMed ID: 6418767
    [Abstract] [Full Text] [Related]

  • 26. The role of anti-complement factor H antibodies in the development of atypical haemolytic uremic syndrome: a possible contribution to abnormality of platelet function.
    Fujisawa M, Yasumoto A, Kato H, Sugawara Y, Yoshida Y, Yatomi Y, Nangaku M.
    Br J Haematol; 2020 Apr; 189(1):182-186. PubMed ID: 31879952
    [Abstract] [Full Text] [Related]

  • 27. Alternative complement pathway hemolytic assays reveal incomplete complement blockade in patients treated with eculizumab.
    Puissant-Lubrano B, Puissochet S, Congy-Jolivet N, Chauveau D, Decramer S, Garnier A, Huart A, Kamar N, Ribes D, Blancher A.
    Clin Immunol; 2017 Oct; 183():1-7. PubMed ID: 28647502
    [Abstract] [Full Text] [Related]

  • 28. Distal Angiopathy and Atypical Hemolytic Uremic Syndrome: Clinical and Functional Properties of an Anti-Factor H IgAλ Antibody.
    Rigothier C, Delmas Y, Roumenina LT, Contin-Bordes C, Lepreux S, Bridoux F, Goujon JM, Bachelet T, Touchard G, Frémeaux-Bacchi V, Combe C.
    Am J Kidney Dis; 2015 Aug; 66(2):331-6. PubMed ID: 26015278
    [Abstract] [Full Text] [Related]

  • 29. Eculizumab in an anephric patient with atypical haemolytic uraemic syndrome and advanced vascular lesions.
    Békássy ZD, Kristoffersson AC, Cronqvist M, Roumenina LT, Rybkine T, Vergoz L, Hue C, Fremeaux-Bacchi V, Karpman D.
    Nephrol Dial Transplant; 2013 Nov; 28(11):2899-907. PubMed ID: 24009284
    [Abstract] [Full Text] [Related]

  • 30. Factor D Inhibition Blocks Complement Activation Induced by Mutant Factor B Associated With Atypical Hemolytic Uremic Syndrome and Membranoproliferative Glomerulonephritis.
    Aradottir SS, Kristoffersson AC, Roumenina LT, Bjerre A, Kashioulis P, Palsson R, Karpman D.
    Front Immunol; 2021 Nov; 12():690821. PubMed ID: 34177949
    [Abstract] [Full Text] [Related]

  • 31. Eculizumab therapy for atypical haemolytic uraemic syndrome due to a gain-of-function mutation of complement factor B.
    Gilbert RD, Fowler DJ, Angus E, Hardy SA, Stanley L, Goodship TH.
    Pediatr Nephrol; 2013 Aug; 28(8):1315-8. PubMed ID: 23624872
    [Abstract] [Full Text] [Related]

  • 32. Complement factor B mutations in atypical hemolytic uremic syndrome-disease-relevant or benign?
    Marinozzi MC, Vergoz L, Rybkine T, Ngo S, Bettoni S, Pashov A, Cayla M, Tabarin F, Jablonski M, Hue C, Smith RJ, Noris M, Halbwachs-Mecarelli L, Donadelli R, Fremeaux-Bacchi V, Roumenina LT.
    J Am Soc Nephrol; 2014 Sep; 25(9):2053-65. PubMed ID: 24652797
    [Abstract] [Full Text] [Related]

  • 33. The MFHR1 Fusion Protein Is a Novel Synthetic Multitarget Complement Inhibitor with Therapeutic Potential.
    Michelfelder S, Fischer F, Wäldin A, Hörle KV, Pohl M, Parsons J, Reski R, Decker EL, Zipfel PF, Skerka C, Häffner K.
    J Am Soc Nephrol; 2018 Apr; 29(4):1141-1153. PubMed ID: 29335241
    [Abstract] [Full Text] [Related]

  • 34. Monitoring of complement activation biomarkers and eculizumab in complement-mediated renal disorders.
    Wehling C, Amon O, Bommer M, Hoppe B, Kentouche K, Schalk G, Weimer R, Wiesener M, Hohenstein B, Tönshoff B, Büscher R, Fehrenbach H, Gök ÖN, Kirschfink M.
    Clin Exp Immunol; 2017 Feb; 187(2):304-315. PubMed ID: 27784126
    [Abstract] [Full Text] [Related]

  • 35. The high frequency of complement factor H related CFHR1 gene deletion is restricted to specific subgroups of patients with atypical haemolytic uraemic syndrome.
    Dragon-Durey MA, Blanc C, Marliot F, Loirat C, Blouin J, Sautes-Fridman C, Fridman WH, Frémeaux-Bacchi V.
    J Med Genet; 2009 Jul; 46(7):447-50. PubMed ID: 19435718
    [Abstract] [Full Text] [Related]

  • 36. Patient stratification and therapy in atypical haemolytic uraemic syndrome (aHUS).
    Wong E, Challis R, Sheerin N, Johnson S, Kavanagh D, Goodship TH.
    Immunobiology; 2016 Jun; 221(6):715-8. PubMed ID: 26037115
    [Abstract] [Full Text] [Related]

  • 37. Clinical and Immunological Profile of Anti-factor H Antibody Associated Atypical Hemolytic Uremic Syndrome: A Nationwide Database.
    Puraswani M, Khandelwal P, Saini H, Saini S, Gurjar BS, Sinha A, Shende RP, Maiti TK, Singh AK, Kanga U, Ali U, Agarwal I, Anand K, Prasad N, Rajendran P, Sinha R, Vasudevan A, Saxena A, Agarwal S, Hari P, Sahu A, Rath S, Bagga A.
    Front Immunol; 2019 Jun; 10():1282. PubMed ID: 31231391
    [Abstract] [Full Text] [Related]

  • 38. Liver transplantation for aHUS: still needed in the eculizumab era?
    Coppo R, Bonaudo R, Peruzzi RL, Amore A, Brunati A, Romagnoli R, Salizzoni M, Galbusera M, Gotti E, Daina E, Noris M, Remuzzi G.
    Pediatr Nephrol; 2016 May; 31(5):759-68. PubMed ID: 26604087
    [Abstract] [Full Text] [Related]

  • 39. Genetics and outcome of atypical hemolytic-uremic syndrome in Turkish children: a retrospective study between 2010 and 2017, a single-center experience.
    Conkar S, Mir S, Berdeli A.
    Iran J Kidney Dis; 2019 Sep; 13(5):316-321. PubMed ID: 31705748
    [Abstract] [Full Text] [Related]

  • 40. Potentiation of complement regulator factor H protects human endothelial cells from complement attack in aHUS sera.
    Pouw RB, Brouwer MC, de Gast M, van Beek AE, van den Heuvel LP, Schmidt CQ, van der Ende A, Sánchez-Corral P, Kuijpers TW, Wouters D.
    Blood Adv; 2019 Feb 26; 3(4):621-632. PubMed ID: 30804016
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 13.